Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 101   

Articles published

SLXP 172.81
price chart
Why Salix Pharmaceuticals, Ltd. Stock Was Clobbered in November
What: Shares of Salix Pharmaceuticals (NASDAQ: SLXP ) , a biopharmaceutical company that develops and acquires drugs designed to treat gastrointestinal diseases, was clobbered in November and fell by 29%, based on data from S&P Capital IQ, after the ...
Related articles »  
Why Salix Pharmaceuticals Ltd. Stock Was Throttled
What: Salix Pharmaceuticals (NASDAQ: SLXP ) , a biopharmaceutical company focused on developing and acquiring drugs targeting gastrointestinal diseases, gave its own shareholders indigestion today when the stock plunged as much as 40% on ...
Jefferies Sees Acquisition Of Salix Pharmaceuticals As Being Even More ...  Benzinga
Salix Pharmaceuticals Reports 3Q2014 Results  MarketWatch
Related articles »  
SALIX PHARMACEUTICALS, LTD. SHAREHOLDER ALERT: Rigrodsky & Long ...
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company") (NASDAQ GS: SLXP) regarding possible breaches of fiduciary duties and other ...
All firms are competing to acquire Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)  Inside Trade
Canadian drug maker Valeant buying Salix Pharmaceuticals for $10B  CBC.ca
Stock Analysis on Salix Pharmaceuticals Ltd. (NASDAQ:SLXP)
[Bloomberg] Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)(TREND ANALYSIS), Two top executives at Salix Pharmaceuticals Ltd. who left after accounting errors at the company will walk away with a combined $46 million, following the company's sale to ...
Salix Pharmaceuticals, Ltd. (SLXP) Q1 Earnings Preview: What To Expect
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) is scheduled to announce its financial results for the first quarter of fiscal year 2015 (1QFY15) on Thursday, May 7 after the markets close.
3 Pharma Companies Competing To Acquire Salix Pharmaceuticals, Ltd. : Who ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), a Raleigh-based specialty pharmaceutical company focusing on innovative treatments for various gastrointestinal disorders, has been the top potential takeover target for some of the major pharmaceutical ...
Sale prospects of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)
The Jefferies increased the figure of target price which they had put on Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), from $123 to $138.
Here's Why Salix Pharmaceuticals, Ltd. Executives Received Millions Even After ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) has paid as much as $46 million combined to two of the top executives who left the company following the accounting scandal late last year.
Valeant Plans $1.45B Stock Offering To Fund Salix Buy  Law360 (subscription)
Valeant Pharmaceuticals Teams Up With Ackman As The Salix Pharmaceuticals ...
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) will be sweetening its acquisition offer for Salix Pharmaceuticals, Ltd.
Thursday's Vital Data: Intel Corporation (INTC), Qualcomm, Inc. (QCOM ...  Investorplace.com
Valeant Said to Be Planning to Raise Its Bid for Salix Pharmaceuticals  New York Times
Salix Pharmaceuticals, Ltd Downgraded At UBS
UBS downgrades Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) stock from a Buy to a Hold rating, but increases its price target from $144 to $158.
Valeant Pharmaceuticals Is Kicking Butt, Says Canaccord Genuity  Benzinga